Retatrutide Primary Benefit: Weight loss, boosted metabolism, improved blood sugar, reduced cardiovascular risk. Retatrutide also helps to reduce liver fat content and resolve NAFLD. Dosing: Once a week. Half-life of Retatrutide is 5 days, so effects become greater over time as the product builds up in your system. Benefits: In Phase 1 clinical trials, participants using Retatrutide lost 9 kg in 12 weeks. Participants in Tirzepatide trials took 40 weeks to lose that amount! Retatrutide has potential to be head and shoulders above the other peptides for fat loss. In phase 2 clinical trials of Retatrutide, patients lost an average of 24% of their body weight in 48 weeks at 12 mg a week.  They also reduced their HbA1C (blood sugar), blood pressure, and cholesterol. Retatrutide change in body weight in clinical trials at 48 weeks:
Liver fat decreased by over 80% in 48 weeks and only 4.6% with placebo group. Retatrutide is a triple agonist; it acts on GLP-1 and GIP, as well as glucagon agonists. Glucagon burns more energy and raises metabolism. Bottom line: You will eat less because you feel less hungry.  Retatrutide affects the hunger hormone, ghrelin. If you would like to include intermittent fasting as part of your weight loss plan, this is a great time to start. You will find it much easier while on this peptide. Dosage:  Start with 1-2 mg weekly for at least 4 weeks. If effects become less, increase dosage.  While it’s possible to build up to 12 mg weekly, it usually isn’t desired or needed. Significant benefits and less side effects have been shown while staying at lower doses for a longer period.  If you experience side effects, decrease to the last dose that didn’t create issues.  Can be combined with low doses of Tirzepatide for greater appetite reduction. Side Effects:  Mostly mild to moderate, and less intense at lower doses. Nausea, diarrhea, vomiting, constipation, increased heart rate, increased sweating, skin tingling.  Study dosages ranged from 2 mg to 12 mg per week. Want more information? Phase 1 Clinical Trials: https://www.hcplive.com/view/retatrutide-use-could-contribute-to-nafld-resolution Phase 2 Clinical Trials: https://www.prevention.com/weight-loss/a44359639/retatrutide-eli-lilly-weight-loss-drug/ Research Report: https://www.cell.com/cell-metabolism/pdfExtended/S1550-4131(22)00312-6 https://www.hcplive.com/view/retatrutide-use-could-contribute-to-nafld-resolution |
Here’s a great Reddit article diving into the real differences between the 3 weight loss peptides: https://www.reddit.com/r/Mounjaro/comments/189eheq/comparing_the_big_3_semaglutide_tirzepatide_and/ |
Weight Loss Peptide Comparisons: Semaglutide study participants lost about 15% of their body weight after six months on the medication. Tirzepatide study participants lost up to 23% of their body weight. Retatrutide study participants have lost over 30% of their body weight. Weight Loss Peptide actions: Semaglutide (Ozempic) is a single agonist; is it works on the glucagon-like peptide-1 (GLP-1).  Tirzepatide (Mounjaro) is a dual agonist; it combines GLP-1 with aglucose-dependent insulinotropic polypeptide (GIP).  Retatrutide is a trinost agonist; it acts on GLP-1 and GIP, as well as glucagon agonists. Glucagon burns more energy and raises metabolism.  Retatrutide is a triple agonist; it acts on GLP-1 and GIP, as well as glucagon. Glucagon burns more energy and raises metabolism. |
top of page
Recent Posts
See Allbottom of page
Comments